Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA interference-based technology - Alnylam

Next Previous
Search
Drug Profile

Research programme: RNA interference-based technology - Alnylam

Alternative Names: KC2; MC3; MC3 LNP; MD1; reLNP

Latest Information Update: 11 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer AlCana Technologies; Alnylam Pharmaceuticals; Icahn School of Medicine at Mount Sinai; Massachusetts General Hospital; Massachusetts Institute of Technology; University of Bonn; University of British Columbia
  • Class Small interfering RNA
  • Mechanism of Action CCR2 receptor antagonists; Claudin 3 inhibitors; DNA-directed RNA polymerase inhibitors; RNA interference; TOR1A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Dystonia; Inflammation; Influenza A virus infections

Most Recent Events

  • 17 Jan 2013 No development reported - Preclinical for Cancer in Germany (Parenteral)
  • 16 Jan 2013 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top